Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun;9(3):828-832.
doi: 10.21037/tlcr-20-400.

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer

Santiago Viteri  1 , Carlos Cabrera-Gálvez  1 , Rafael Rosell  2
Affiliations
Editorial

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer

Santiago Viteri et al. Transl Lung Cancer Res. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-400). RR serves as the unpaid Editor-in-Chief of Translational Lung Cancer Research from Jun 2019 to May 2022. SV reports personal fees from AbbVie, personal fees and non-financial support from Bristol-Myers Squibb, personal fees and non-financial support from Roche, personal fees from Merck Sharp & Dohme, non-financial support from OSE Pharma, non-financial support from Merck KGaA, outside the submitted work; CGC reports non-financial support from Merck Sharp & Dohme, non-financial support from Pierre-Fabre Oncology, personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Pfizer, outside the submitted work; RR has nothing to disclose, and RR serves as an unpaid Editor-in-Chief of Translational Lung Cancer Research from Jun 2019 to May 2022.

Comment on

  • Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Paz-Ares L, et al. N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280635 Clinical Trial.

References

    1. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018;379:2040-51. 10.1056/NEJMoa1810865 - DOI - PubMed
    1. Stewart PA, Welsh EA, Slebos RJC, et al. Proteogenomic landscape of squamous cell lung cancer. Nat Commun 2019;10:3578. 10.1038/s41467-019-11452-x - DOI - PMC - PubMed
    1. Available online: https://www.fda.gov/drugs/fda-approves-pembrolizumab-combination-chemoth...
    1. Available online: https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-382...
    1. Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer 2018;6:75. 10.1186/s40425-018-0382-2 - DOI - PMC - PubMed